SHPH Shuttle Pharmaceuticals: Quarterly EPS earnings growth
Shuttle Pharmaceuticals minimizes production risks by outsourcing drug synthesis to US-based cGMP facilities. The quarterly EPS trend displayed on the GURU.Markets platform shows that the 90.20 metric serves as the target level. The humanitarian status of its developments ensures business stability by providing protection from sanctions, while the oncology team effectively optimizes radiation therapy for brain and prostate cancer.
%20Year-over-year%20net%20earnings%20per%20share%20change%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_SHPH_-_Shuttle-Pharmaceuticals_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "SHPH Shuttle Pharmaceuticals Holdings, Inc.: Year-over-year earnings per share growth for the last twelve months in the range 04/28/2023 - 11/12/2026 | 👁️GURU.Markets👁️")
Shuttle Pharmaceuticals Inc (SHPH) - metric breakdowns and financial figures
This indicator measures the quarterly earnings per share (EPS) dynamics, providing an objective assessment of the issuer's ability to generate income relative to historical data. By analyzing the quarterly EPS growth valuation, an investor can correlate the financial stability of Shuttle Pharmaceuticals (SHPH) with the scaling potential of its oncology drugs as they are integrated into global radiotherapy standards.
